However, the two key kinases in Wnt signaling, GSK-3β and CK1α, negatively regulate the Wnt/β-catenin signaling pathway, and therefore cannot serve as therapeutic targets for anti-tumor treatment. The gene discussed is CSNK1A1; the disease is neoplasm.